Read the Full Data Set from Phase IIA Clinical Trial for AL001 at ?? Alzamend.com #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
Alzamend Neuro
生物技术研究
Atlanta，Georgia 1,355 位关注者
Targeting treatment for Alzheimer's Disease, Major Depressive Disorder, Bipolar Disorder, and PTSD.
关于我们
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.?
- 网站
-
https://www.alzamend.com
Alzamend Neuro的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Atlanta，Georgia
- 类型
- 上市公司
- 创立
- 2016
地点
-
主要
获取路线
3480 Peachtree Rd NE
2nd FL, suite 121
US，Georgia，Atlanta，30326
Alzamend Neuro员工
动态
-
The financial implications of Alzheimer’s are overwhelming and become a burden to many families in the U.S. Alzamend is committed to Making Alzheimer’s Just a Memory?? Learn more ?? Alzamend.com #Alzheimers #bipolar #depression #PTSD $ALZN
-
-
Alzamend Neuro is currently working to transition two therapeutics targeting Alzheimer’s disease, Bipolar Disorder, Major Depressive Disorder, and Post-Traumatic Stress Disorder from clinical/non-clinical stages and towards full commercialization. View Alzamend Neuro’s current product pipeline ? Alzamend.com #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
-
-
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice #alzheimers #bipolar #depression #PTSD #clinicaltrials $ALZN https://lnkd.in/et5XbMgd
-
1 in 9 people age 65+ suffer from Alzheimer’s dementia in the U.S. Learn about Alzamend’s commitment to the treatment and cures of Alzheimer’s disease at Alzamend.com #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
-
-
Do you or someone you know suffer from Post-Traumatic Stress Disorder? The earlier a person gets treatment for PTSD, the better their chance of recovery. Visit Alzamend.com to learn more #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
-
-
Alzamend is committed to Making Alzheimer’s Just a Memory?? ?? Learn more about Alzamend and it’s mission to rapidly develop market safe and effective treatments at Alzamend.com #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
-
-
You are not alone ?? Alzamend is committed to the treatments and cures of Alzheimer’s disease, Bipolar Disorder, Major Depressive Disorder, and Post-Traumatic Stress Disorder. Learn more at Alzamend.com #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
-
-
Here is what CEO of Alzamend, Stephan Jackman had to say when Alzamend Neuro announced the Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001. Review the Full Data Set from AL001 Clinical Trial ?? https://lnkd.in/gqXWpF_N #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
-
-
??Data confirms the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee. ??Identified dose is unlikely to require lithium therapeutic drug monitoring ?? Data will guide upcoming “Lithium in Brain” Phase II clinical trials in partnership with Massachusetts General Hospital Review the Full Data Set from AL001 Clinical Trial ?? https://lnkd.in/gqXWpF_N #Alzheimers #bipolar #depression #PTSD $ALZN #alzheimersawarenessmonth
-
-
-
-
-
+3
-